Patents by Inventor Julia BOSHUIZEN

Julia BOSHUIZEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
    Publication number: 20230321261
    Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.
    Type: Application
    Filed: September 30, 2022
    Publication date: October 12, 2023
    Inventors: Julia BOSHUIZEN, Esther BREIJ, Louise KOOPMAN, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rob DE JONG, Riemke VAN DIJKHUIZEN RADERSMA, Daniel PEEPER, Paul PARREN
  • AXL ANTIBODY-DRUG CONJUGATES FOR USE IN TREATING CANCER
    Publication number: 20220273809
    Abstract: The present invention relates to conjugates of antibodies and cytotoxic agents for use in treatment of cancer in combination with an inhibitor of PD-1 or PD-L1. The antibodies are directed against Axl.
    Type: Application
    Filed: July 17, 2020
    Publication date: September 1, 2022
    Inventors: Maarten JANMAAT, Nora PENCHEVA, Esther Cornelia Wilhelmina BREIJ, Julia BOSHUIZEN, Daniel Simon PEEPER, Ulf FORSSMANN, Tahamtan AHMADI, Patricia Garrido CASTRO
  • AXL-SPECIFIC ANTIBODIES FOR CANCER TREATMENT
    Publication number: 20210070869
    Abstract: The disclosure relates to anti-AXL antibodies, immunoconjugates, and compositions for treatment of cancer, which is resistant to or is predicted to be or become resistant to treatment with a programmed cell death-1/programmed cell death-1 ligand (PD-1/PD-L1) inhibitor.
    Type: Application
    Filed: April 10, 2019
    Publication date: March 11, 2021
    Inventors: Maarten JANMAAT, Esther BREIJ, Ulf FORSSMANN, Tahamtan AHMADI, Julia BOSHUIZEN, Daniel PEEPER, Nora PENCHEVA
  • AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
    Publication number: 20200397913
    Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of resistant or refractory cancers.
    Type: Application
    Filed: June 3, 2020
    Publication date: December 24, 2020
    Inventors: Julia BOSHUIZEN, Kirstine JACOBSEN, Esther BREIJ, Louise KOOPMAN, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rob DE JONG, Riemke VAN DIJKHUIZEN RADERSMA, Daniel Simon PEEPER, Henrik Jørn DITZEL, Paul PARREN
  • AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
    Publication number: 20190022243
    Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 24, 2019
    Inventors: Julia BOSHUIZEN, Esther BREIJ, Louise KOOPMAN, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rob DE JONG, Riemke VAN DIJKHUIZEN RADERSMA, Daniel PEEPER, Paul PARREN
  • AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
    Publication number: 20180326084
    Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of resistant or refractory cancers.
    Type: Application
    Filed: July 8, 2016
    Publication date: November 15, 2018
    Inventors: Julia BOSHUIZEN, Kirstine JACOBSEN, Esther BREIJ, Louise KOOPMAN, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rob DE JONG, Riemke VAN DIJKHUIZEN RADERSMA, Daniel PEEPER, Henrik Jørn DITZEL, Paul PARREN